Clinical trials in various cancer patients have failed, with monoclonal antibodies targeting only IGF-1R without IR (25,26,27) due to the advancement of tumor growth, most likely arising from the escape mechanism involving insulin [63,64]. This evidence concerns the gene IGF1R and neoplasm.